#begin document (ectb_1029_3); part 000
ectb_1029	3	0	Where	-
ectb_1029	3	1	the	-
ectb_1029	3	2	real	-
ectb_1029	3	3	money	-
ectb_1029	3	4	is	-

ectb_1029	3	0	At	-
ectb_1029	3	1	present	-
ectb_1029	3	2	,	-
ectb_1029	3	3	most	-
ectb_1029	3	4	applications	-
ectb_1029	3	5	for	-
ectb_1029	3	6	biochips	(35)
ectb_1029	3	7	are	-
ectb_1029	3	8	in	-
ectb_1029	3	9	academic	-
ectb_1029	3	10	research	-
ectb_1029	3	11	and	-
ectb_1029	3	12	the	-
ectb_1029	3	13	development	-
ectb_1029	3	14	of	-
ectb_1029	3	15	new	-
ectb_1029	3	16	pharmaceutical	-
ectb_1029	3	17	drugs	-
ectb_1029	3	18	.	-

ectb_1029	3	0	Demand	-
ectb_1029	3	1	for	-
ectb_1029	3	2	them	(35)
ectb_1029	3	3	is	-
ectb_1029	3	4	growing	-
ectb_1029	3	5	rapidly	-
ectb_1029	3	6	.	-

ectb_1029	3	0	Johnsee	-
ectb_1029	3	1	Lee	-
ectb_1029	3	2	says	-
ectb_1029	3	3	that	-
ectb_1029	3	4	according	-
ectb_1029	3	5	to	-
ectb_1029	3	6	US	-
ectb_1029	3	7	market	-
ectb_1029	3	8	research	-
ectb_1029	3	9	estimates	-
ectb_1029	3	10	,	-
ectb_1029	3	11	the	(9
ectb_1029	3	12	worldwide	-
ectb_1029	3	13	annual	-
ectb_1029	3	14	consumption	-
ectb_1029	3	15	of	-
ectb_1029	3	16	microarray	-
ectb_1029	3	17	chips	9)
ectb_1029	3	18	is	-
ectb_1029	3	19	currently	-
ectb_1029	3	20	around	-
ectb_1029	3	21	250,000	-
ectb_1029	3	22	;	-
ectb_1029	3	23	in	-
ectb_1029	3	24	two	-
ectb_1029	3	25	years	-
ectb_1029	3	26	this	(9)
ectb_1029	3	27	is	-
ectb_1029	3	28	expected	-
ectb_1029	3	29	to	-
ectb_1029	3	30	grow	-
ectb_1029	3	31	to	-
ectb_1029	3	32	1.2	-
ectb_1029	3	33	million	-
ectb_1029	3	34	.	-

ectb_1029	3	0	Based	-
ectb_1029	3	1	on	-
ectb_1029	3	2	a	-
ectb_1029	3	3	market	-
ectb_1029	3	4	price	-
ectb_1029	3	5	per	-
ectb_1029	3	6	chip	-
ectb_1029	3	7	of	-
ectb_1029	3	8	US$	-
ectb_1029	3	9	1,000	-
ectb_1029	3	10	,	-
ectb_1029	3	11	the	-
ectb_1029	3	12	size	-
ectb_1029	3	13	of	-
ectb_1029	3	14	the	-
ectb_1029	3	15	world	-
ectb_1029	3	16	market	-
ectb_1029	3	17	in	-
ectb_1029	3	18	biochips	-
ectb_1029	3	19	could	-
ectb_1029	3	20	grow	-
ectb_1029	3	21	to	-
ectb_1029	3	22	US$	-
ectb_1029	3	23	1.2	-
ectb_1029	3	24	billion	-
ectb_1029	3	25	in	-
ectb_1029	3	26	2003	-
ectb_1029	3	27	,	-
ectb_1029	3	28	and	-
ectb_1029	3	29	to	-
ectb_1029	3	30	US$	-
ectb_1029	3	31	40	-
ectb_1029	3	32	billion	-
ectb_1029	3	33	over	-
ectb_1029	3	34	the	-
ectb_1029	3	35	next	-
ectb_1029	3	36	decade	-
ectb_1029	3	37	.	-

ectb_1029	3	0	Thus	-
ectb_1029	3	1	some	(36
ectb_1029	3	2	people	36)
ectb_1029	3	3	have	-
ectb_1029	3	4	set	-
ectb_1029	3	5	their	(36)
ectb_1029	3	6	sights	-
ectb_1029	3	7	on	-
ectb_1029	3	8	the	-
ectb_1029	3	9	biochip	-
ectb_1029	3	10	market	-
ectb_1029	3	11	,	-
ectb_1029	3	12	and	-
ectb_1029	3	13	believe	-
ectb_1029	3	14	that	-
ectb_1029	3	15	following	-
ectb_1029	3	16	Taiwan	(24
ectb_1029	3	17	's	24)
ectb_1029	3	18	success	-
ectb_1029	3	19	in	-
ectb_1029	3	20	the	-
ectb_1029	3	21	semiconductor	-
ectb_1029	3	22	field	-
ectb_1029	3	23	,	-
ectb_1029	3	24	the	(24
ectb_1029	3	25	island	24)
ectb_1029	3	26	could	-
ectb_1029	3	27	go	-
ectb_1029	3	28	on	-
ectb_1029	3	29	to	-
ectb_1029	3	30	be	-
ectb_1029	3	31	a	-
ectb_1029	3	32	major	-
ectb_1029	3	33	center	-
ectb_1029	3	34	for	-
ectb_1029	3	35	contract	-
ectb_1029	3	36	manufacture	-
ectb_1029	3	37	of	-
ectb_1029	3	38	biochips	-
ectb_1029	3	39	.	-

ectb_1029	3	0	Be	-
ectb_1029	3	1	that	-
ectb_1029	3	2	as	-
ectb_1029	3	3	it	-
ectb_1029	3	4	may	-
ectb_1029	3	5	,	-
ectb_1029	3	6	the	(11
ectb_1029	3	7	small	-
ectb_1029	3	8	number	-
ectb_1029	3	9	of	-
ectb_1029	3	10	biochip	-
ectb_1029	3	11	companies	-
ectb_1029	3	12	so	-
ectb_1029	3	13	far	-
ectb_1029	3	14	established	-
ectb_1029	3	15	in	-
ectb_1029	3	16	Taiwan	(24)|11)
ectb_1029	3	17	still	-
ectb_1029	3	18	find	-
ectb_1029	3	19	their	(11)
ectb_1029	3	20	market	-
ectb_1029	3	21	in	-
ectb_1029	3	22	domestic	-
ectb_1029	3	23	research	-
ectb_1029	3	24	establishments	-
ectb_1029	3	25	and	-
ectb_1029	3	26	pharmaceuticals	-
ectb_1029	3	27	manufacturers	-
ectb_1029	3	28	.	-

ectb_1029	3	0	Although	-
ectb_1029	3	1	they	(11)
ectb_1029	3	2	are	-
ectb_1029	3	3	also	-
ectb_1029	3	4	actively	-
ectb_1029	3	5	developing	-
ectb_1029	3	6	overseas	-
ectb_1029	3	7	markets	-
ectb_1029	3	8	,	-
ectb_1029	3	9	what	-
ectb_1029	3	10	interests	-
ectb_1029	3	11	them	(11)
ectb_1029	3	12	most	-
ectb_1029	3	13	is	-
ectb_1029	3	14	not	-
ectb_1029	3	15	biochips	(28)
ectb_1029	3	16	per	-
ectb_1029	3	17	se	-
ectb_1029	3	18	,	-
ectb_1029	3	19	nor	-
ectb_1029	3	20	are	-
ectb_1029	3	21	they	(11)
ectb_1029	3	22	content	-
ectb_1029	3	23	merely	-
ectb_1029	3	24	to	-
ectb_1029	3	25	be	-
ectb_1029	3	26	contract	-
ectb_1029	3	27	manufacturers	-
ectb_1029	3	28	.	-

ectb_1029	3	0	"	-
ectb_1029	3	1	The	(28
ectb_1029	3	2	chips	28)
ectb_1029	3	3	are	-
ectb_1029	3	4	only	-
ectb_1029	3	5	a	-
ectb_1029	3	6	tool	-
ectb_1029	3	7	,	-
ectb_1029	3	8	and	-
ectb_1029	3	9	the	-
ectb_1029	3	10	big	-
ectb_1029	3	11	money	-
ectb_1029	3	12	is	-
ectb_1029	3	13	not	-
ectb_1029	3	14	in	-
ectb_1029	3	15	chip	-
ectb_1029	3	16	sales	-
ectb_1029	3	17	.	-

ectb_1029	3	0	What	-
ectb_1029	3	1	counts	-
ectb_1029	3	2	is	-
ectb_1029	3	3	the	-
ectb_1029	3	4	R&D	-
ectb_1029	3	5	behind	-
ectb_1029	3	6	them	(28)
ectb_1029	3	7	.	-
ectb_1029	3	8	"	-

ectb_1029	3	0	Jerry	(22
ectb_1029	3	1	Huang	-
ectb_1029	3	2	,	-
ectb_1029	3	3	executive	-
ectb_1029	3	4	vice	-
ectb_1029	3	5	president	-
ectb_1029	3	6	of	-
ectb_1029	3	7	U	(14
ectb_1029	3	8	-	-
ectb_1029	3	9	Vision	-
ectb_1029	3	10	Biotech	22)|14)
ectb_1029	3	11	,	-
ectb_1029	3	12	reveals	-
ectb_1029	3	13	that	-
ectb_1029	3	14	U	(14
ectb_1029	3	15	-	-
ectb_1029	3	16	Vision	-
ectb_1029	3	17	,	-
ectb_1029	3	18	which	-
ectb_1029	3	19	was	-
ectb_1029	3	20	set	-
ectb_1029	3	21	up	-
ectb_1029	3	22	in	-
ectb_1029	3	23	September	-
ectb_1029	3	24	1999	14)
ectb_1029	3	25	,	-
ectb_1029	3	26	has	-
ectb_1029	3	27	signed	-
ectb_1029	3	28	a	-
ectb_1029	3	29	contract	-
ectb_1029	3	30	with	-
ectb_1029	3	31	the	-
ectb_1029	3	32	US	-
ectb_1029	3	33	company	-
ectb_1029	3	34	Zen	-
ectb_1029	3	35	-	-
ectb_1029	3	36	Bio	-
ectb_1029	3	37	to	-
ectb_1029	3	38	jointly	-
ectb_1029	3	39	develop	-
ectb_1029	3	40	human	-
ectb_1029	3	41	adipocyte	-
ectb_1029	3	42	cDNA	-
ectb_1029	3	43	microarray	-
ectb_1029	3	44	chips	-
ectb_1029	3	45	.	-

ectb_1029	3	0	Huang	(22)
ectb_1029	3	1	states	-
ectb_1029	3	2	that	-
ectb_1029	3	3	research	-
ectb_1029	3	4	in	-
ectb_1029	3	5	recent	-
ectb_1029	3	6	years	-
ectb_1029	3	7	has	-
ectb_1029	3	8	revealed	-
ectb_1029	3	9	that	-
ectb_1029	3	10	adipocytes	-
ectb_1029	3	11	-LRB-	-
ectb_1029	3	12	fat	-
ectb_1029	3	13	cells	-
ectb_1029	3	14	-RRB-	-
ectb_1029	3	15	are	-
ectb_1029	3	16	active	-
ectb_1029	3	17	regulators	-
ectb_1029	3	18	of	-
ectb_1029	3	19	the	-
ectb_1029	3	20	energy	-
ectb_1029	3	21	balance	-
ectb_1029	3	22	in	-
ectb_1029	3	23	the	-
ectb_1029	3	24	body	-
ectb_1029	3	25	,	-
ectb_1029	3	26	and	-
ectb_1029	3	27	play	-
ectb_1029	3	28	an	-
ectb_1029	3	29	important	-
ectb_1029	3	30	role	-
ectb_1029	3	31	in	-
ectb_1029	3	32	disorders	(29
ectb_1029	3	33	such	-
ectb_1029	3	34	as	-
ectb_1029	3	35	obesity	-
ectb_1029	3	36	,	-
ectb_1029	3	37	diabetes	-
ectb_1029	3	38	,	-
ectb_1029	3	39	osteoporosis	-
ectb_1029	3	40	and	-
ectb_1029	3	41	cardiovascular	-
ectb_1029	3	42	disease	29)
ectb_1029	3	43	.	-

ectb_1029	3	0	Thus	-
ectb_1029	3	1	it	-
ectb_1029	3	2	is	-
ectb_1029	3	3	hoped	-
ectb_1029	3	4	that	-
ectb_1029	3	5	research	-
ectb_1029	3	6	into	-
ectb_1029	3	7	human	-
ectb_1029	3	8	adipocytes	-
ectb_1029	3	9	can	-
ectb_1029	3	10	help	-
ectb_1029	3	11	in	-
ectb_1029	3	12	the	-
ectb_1029	3	13	search	-
ectb_1029	3	14	for	-
ectb_1029	3	15	drugs	-
ectb_1029	3	16	and	-
ectb_1029	3	17	other	-
ectb_1029	3	18	therapies	-
ectb_1029	3	19	to	-
ectb_1029	3	20	treat	-
ectb_1029	3	21	these	(29
ectb_1029	3	22	disorders	29)
ectb_1029	3	23	.	-

ectb_1029	3	0	Apart	-
ectb_1029	3	1	from	-
ectb_1029	3	2	this	-
ectb_1029	3	3	,	-
ectb_1029	3	4	U	(14
ectb_1029	3	5	-	-
ectb_1029	3	6	Vision	14)
ectb_1029	3	7	is	-
ectb_1029	3	8	also	-
ectb_1029	3	9	conducting	-
ectb_1029	3	10	a	-
ectb_1029	3	11	one	-
ectb_1029	3	12	-	-
ectb_1029	3	13	year	-
ectb_1029	3	14	bacterial	-
ectb_1029	3	15	genome	-
ectb_1029	3	16	project	-
ectb_1029	3	17	,	-
ectb_1029	3	18	which	-
ectb_1029	3	19	aims	-
ectb_1029	3	20	to	-
ectb_1029	3	21	map	-
ectb_1029	3	22	the	-
ectb_1029	3	23	genome	-
ectb_1029	3	24	of	-
ectb_1029	3	25	a	-
ectb_1029	3	26	certain	-
ectb_1029	3	27	drug	-
ectb_1029	3	28	-	-
ectb_1029	3	29	resistant	-
ectb_1029	3	30	bacterium	-
ectb_1029	3	31	as	-
ectb_1029	3	32	a	-
ectb_1029	3	33	basis	-
ectb_1029	3	34	for	-
ectb_1029	3	35	developing	-
ectb_1029	3	36	new	-
ectb_1029	3	37	vaccines	-
ectb_1029	3	38	and	-
ectb_1029	3	39	drugs	-
ectb_1029	3	40	.	-

ectb_1029	3	0	Drug	-
ectb_1029	3	1	development	-

ectb_1029	3	0	Taiwan	(13
ectb_1029	3	1	Genome	-
ectb_1029	3	2	Sciences	-
ectb_1029	3	3	-LRB-	-
ectb_1029	3	4	TGS	-
ectb_1029	3	5	-RRB-	-
ectb_1029	3	6	,	-
ectb_1029	3	7	which	-
ectb_1029	3	8	was	-
ectb_1029	3	9	set	-
ectb_1029	3	10	up	-
ectb_1029	3	11	in	-
ectb_1029	3	12	November	-
ectb_1029	3	13	1999	-
ectb_1029	3	14	as	-
ectb_1029	3	15	a	-
ectb_1029	3	16	joint	-
ectb_1029	3	17	venture	-
ectb_1029	3	18	by	-
ectb_1029	3	19	the	-
ectb_1029	3	20	Uni-President	-
ectb_1029	3	21	Enterprises	-
ectb_1029	3	22	Group	-
ectb_1029	3	23	,	-
ectb_1029	3	24	Yuen	-
ectb_1029	3	25	Foong	-
ectb_1029	3	26	Yu	-
ectb_1029	3	27	and	-
ectb_1029	3	28	Tuntex	-
ectb_1029	3	29	Groups	13)
ectb_1029	3	30	,	-
ectb_1029	3	31	only	-
ectb_1029	3	32	entered	-
ectb_1029	3	33	the	-
ectb_1029	3	34	biotechnology	-
ectb_1029	3	35	fray	-
ectb_1029	3	36	in	-
ectb_1029	3	37	April	-
ectb_1029	3	38	of	-
ectb_1029	3	39	this	-
ectb_1029	3	40	year	-
ectb_1029	3	41	.	-

ectb_1029	3	0	CEO	(2
ectb_1029	3	1	Andrew	-
ectb_1029	3	2	Kuo	2)
ectb_1029	3	3	says	-
ectb_1029	3	4	the	(34
ectb_1029	3	5	investors	34)
ectb_1029	3	6	came	-
ectb_1029	3	7	to	-
ectb_1029	3	8	the	-
ectb_1029	3	9	view	-
ectb_1029	3	10	that	-
ectb_1029	3	11	Taiwan	(24)
ectb_1029	3	12	needs	-
ectb_1029	3	13	to	-
ectb_1029	3	14	develop	-
ectb_1029	3	15	its	(24)
ectb_1029	3	16	biotechnology	-
ectb_1029	3	17	industries	-
ectb_1029	3	18	,	-
ectb_1029	3	19	and	-
ectb_1029	3	20	therefore	-
ectb_1029	3	21	they	(34)
ectb_1029	3	22	combined	-
ectb_1029	3	23	their	(34)
ectb_1029	3	24	resources	-
ectb_1029	3	25	to	-
ectb_1029	3	26	make	-
ectb_1029	3	27	a	-
ectb_1029	3	28	long	-
ectb_1029	3	29	-	-
ectb_1029	3	30	term	-
ectb_1029	3	31	investment	-
ectb_1029	3	32	in	-
ectb_1029	3	33	the	-
ectb_1029	3	34	field	-
ectb_1029	3	35	.	-

ectb_1029	3	0	TGS	(13
ectb_1029	3	1	's	13)
ectb_1029	3	2	strategy	-
ectb_1029	3	3	is	-
ectb_1029	3	4	to	-
ectb_1029	3	5	invest	-
ectb_1029	3	6	in	-
ectb_1029	3	7	a	(20
ectb_1029	3	8	number	-
ectb_1029	3	9	of	-
ectb_1029	3	10	US	-
ectb_1029	3	11	genome	-
ectb_1029	3	12	research	-
ectb_1029	3	13	companies	20)
ectb_1029	3	14	,	-
ectb_1029	3	15	and	-
ectb_1029	3	16	to	-
ectb_1029	3	17	sign	-
ectb_1029	3	18	technology	-
ectb_1029	3	19	transfer	-
ectb_1029	3	20	agreements	-
ectb_1029	3	21	and	-
ectb_1029	3	22	chip	-
ectb_1029	3	23	production	-
ectb_1029	3	24	contracts	-
ectb_1029	3	25	with	-
ectb_1029	3	26	them	(20)
ectb_1029	3	27	.	-

ectb_1029	3	0	Kuo	(2)
ectb_1029	3	1	comments	-
ectb_1029	3	2	that	-
ectb_1029	3	3	contract	-
ectb_1029	3	4	production	-
ectb_1029	3	5	of	-
ectb_1029	3	6	chips	-
ectb_1029	3	7	is	-
ectb_1029	3	8	merely	-
ectb_1029	3	9	a	-
ectb_1029	3	10	service	-
ectb_1029	3	11	activity	-
ectb_1029	3	12	and	-
ectb_1029	3	13	a	-
ectb_1029	3	14	source	-
ectb_1029	3	15	of	-
ectb_1029	3	16	income	-
ectb_1029	3	17	for	-
ectb_1029	3	18	the	(13
ectb_1029	3	19	company	13)
ectb_1029	3	20	-	-
ectb_1029	3	21	TGS	(13
ectb_1029	3	22	's	13)
ectb_1029	3	23	ultimate	-
ectb_1029	3	24	goal	-
ectb_1029	3	25	is	-
ectb_1029	3	26	in	-
ectb_1029	3	27	doing	-
ectb_1029	3	28	R&D	-
ectb_1029	3	29	work	-
ectb_1029	3	30	to	-
ectb_1029	3	31	identify	-
ectb_1029	3	32	gene	-
ectb_1029	3	33	sequences	-
ectb_1029	3	34	as	-
ectb_1029	3	35	targets	-
ectb_1029	3	36	for	-
ectb_1029	3	37	developing	-
ectb_1029	3	38	new	-
ectb_1029	3	39	drugs	-
ectb_1029	3	40	.	-

ectb_1029	3	0	Kuo	(2)
ectb_1029	3	1	states	-
ectb_1029	3	2	that	-
ectb_1029	3	3	at	-
ectb_1029	3	4	present	-
ectb_1029	3	5	,	-
ectb_1029	3	6	the	-
ectb_1029	3	7	number	-
ectb_1029	3	8	of	-
ectb_1029	3	9	known	-
ectb_1029	3	10	target	-
ectb_1029	3	11	sequences	-
ectb_1029	3	12	for	-
ectb_1029	3	13	disease	-
ectb_1029	3	14	-	-
ectb_1029	3	15	treating	-
ectb_1029	3	16	drugs	-
ectb_1029	3	17	is	-
ectb_1029	3	18	only	-
ectb_1029	3	19	around	-
ectb_1029	3	20	500	-
ectb_1029	3	21	,	-
ectb_1029	3	22	but	-
ectb_1029	3	23	as	-
ectb_1029	3	24	the	-
ectb_1029	3	25	human	-
ectb_1029	3	26	genome	-
ectb_1029	3	27	is	-
ectb_1029	3	28	mapped	-
ectb_1029	3	29	out	-
ectb_1029	3	30	this	-
ectb_1029	3	31	number	-
ectb_1029	3	32	can	-
ectb_1029	3	33	be	-
ectb_1029	3	34	expected	-
ectb_1029	3	35	to	-
ectb_1029	3	36	increase	-
ectb_1029	3	37	tenfold	-
ectb_1029	3	38	.	-

ectb_1029	3	0	Currently	-
ectb_1029	3	1	,	-
ectb_1029	3	2	TGS	(13)
ectb_1029	3	3	has	-
ectb_1029	3	4	its	(13)
ectb_1029	3	5	sights	-
ectb_1029	3	6	set	-
ectb_1029	3	7	mainly	-
ectb_1029	3	8	on	-
ectb_1029	3	9	doing	-
ectb_1029	3	10	research	-
ectb_1029	3	11	into	-
ectb_1029	3	12	diseases	-
ectb_1029	3	13	which	-
ectb_1029	3	14	are	-
ectb_1029	3	15	especially	-
ectb_1029	3	16	prevalent	-
ectb_1029	3	17	in	-
ectb_1029	3	18	Asia	-
ectb_1029	3	19	,	-
ectb_1029	3	20	such	-
ectb_1029	3	21	as	-
ectb_1029	3	22	liver	-
ectb_1029	3	23	and	-
ectb_1029	3	24	stomach	-
ectb_1029	3	25	cancers	-
ectb_1029	3	26	.	-

#end document
